Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2016

Enterprise-wide Disclosures [Abstract]

Total revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor (in thousands):

	Revenues for the Year Ended December 31,
Geographic Area	2016		2015		2014
Domestic	$	4,497	$	5,976	$	3,586
Asia		1,426		1,060		1,658
Total revenues	$	5,923	$	7,036	$	5,244

The composition of BioTime’s long-lived assets, consisting of property, plant and equipment, net, between those in the United States and in foreign countries is set forth below (in thousands):

	2016⁽¹⁾		2015
Domestic	$	3,418	$	7,132
Foreign		2,111		407
Total	$	5,529	$	7,539

(1) Reflects the effect of the Asterias Deconsolidation.

Sources of Revenues

The following table shows the sources of BioTime’s revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2016, 2015, and 2014:

	Revenues for the Year Ended December 31,
Sources of Revenues	2016		2015		2014
CIRM grant income		38.0%		42.7%		19.7%
NIH grant income		-%		6.5%		12.5%
IIA (formerly OCS) grant income (Cell Cure, Israel)		24.0%		14.4%		31.3%
Subscriptions, advertising and other (various customers) ⁽¹⁾		35.0%		29.4%		32.5%
Other ⁽¹⁾		3.0%		7.0%		4.0%

(1)

No individual customer greater than 5% of total revenues.